AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
com 30 Financial Review Introduction Our operations are focused on prescription The adverse impact on pharmaceutical The purpose of the Financial Review is to pharmaceuticals and more than 97% of our prices as a result of the regulatory provide understanding and analysis of our sales are made in that sector.
Although there is no direct results for the year 2002 and of the progress pharmaceutical products tend to be relatively governmental control on prices in the US, made since 2001.
It also provides details of insensitive to general economic pressures from individual state material changes in financial performance circumstances in the short term.
They are programmes and health insurance between 2001 and 2000.
The Financial more directly influenced by medical needs bodies are leading to downward forces Review describes: and are generally financed by health on realised prices.
In other parts of the insurance schemes or national healthcare world there are a variety of price and Business events influencing 2002: budgets.
volume control mechanisms and page 30 retrospective rebates based on sales However, we are exposed to currency levels which are imposed by Results of operations 2000-2002 in fluctuations which can significantly affect our governments.
tabular form: pages 30 and 31 results.
We report our activities in US dollars as this is our single largest currency and best Over the longer term, the success of our Results of operations analysis of year reflects our currency exposure.
research and development is crucial.
In to 31 December 2002: page 31 common with other pharmaceutical The fluctuation of currencies against the US companies we devote substantial resources Financial position: page 34 dollar consequently causes variation in our to R&D, the benefit of which emerges over the financial results principally because a long term and carries considerable Liquidity and capital resources 2000- substantial part of our income is denominated uncertainty as to whether it will generate 2002: page 34 in US dollars whereas a large part of our cost future products.
base is in sterling and Swedish kronor.
During Financial policies: page 34 2002, there was a significant weakening of In 2002, the business events which had most the US dollar, particularly as compared with significance for our financial results are Critical accounting policies and the euro, Swedish kronor and sterling.
described briefly in the following paragraphs.
estimates: page 37 Although this has had the effect of increasing the dollar value of our European sales The key business priority is the transformation Off balance sheet transactions, compared with 2001 it means our UK and of our product portfolio whereby existing contingent liabilities and commitments: Swedish costs have also increased growth products and the late stage product page 38 correspondingly.
Our approach to managing pipeline replace the loss of sales from currency exposures is described below in the products facing generic competition.
New accounting standards: page 39 Financial Policies section.
The net impact of currency fluctuations on profit compared with In the US, which is our largest market International accounting: page 40.
accounting for 52% of sales, Faslodex was launched in April 2002 whilst Nexium, Additionally, in accordance with US requirements: In addition to fluctuating exchange rates, our Seroquel and Toprol-XL sales continued to operating results in the short term can be grow strongly.
We had planned to launch Results of operations analysis of year to affected by a number of factors other than Crestor and Iressa in the second half of the 31 December 2001: page 40 normal competition: year but, as described elsewhere in this report, FDA approval of these products is US GAAP information 2000-2002: Risk of loss or expiration of patents and now expected in 2003. page 42. the potential adverse effect on sales volumes and prices from generic Our US product portfolio faces generic Business events influencing 2002 competition: competition on three products Zestril in The business background is described in the 2002, Nolvadex in 2003 and Prilosec.
The Operational Review sections to this report.
The costs associated with new product Prilosec situation is described in detail on The following comments highlight how these launches, the timings of those launches page 31 and we have had generic and other factors affect our financial and the risk that such new products do omeprazole competition from December performance.
not succeed as anticipated: and 2002 although this had no impact on AstraZeneca sales 2002 2001 2000 reclassified reclassified $m $m $m Continuing operations 17,841 16,222 15,583 Agrochemicals discontinued 2,299 17,841 16,222 17,882 AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
com 31 reported sales in the year.
Prilosec sales cost of sales have been reduced by $287 growth products we highlight in our portfolio declined 21% as a result of patients switching million in the current year 2001 $258 million, Casodex, Arimidex, Atacand, Seroquel and to Nexium during the year and competition 2000 $221 million.
The change has minimal Zomig grew by another $900 million to just from other products.
Zestril sales have fallen impact on previously stated sales growth over $3 billion in aggregate.
Together they sharply since the lisinopril patent expired in rates.
Furthermore, neither profits nor net comprise a solid foundation upon which to June 2002.
The patent for Nolvadex expired assets have been affected.
in August 2002, but the FDA granted a further six months exclusivity following work on the Results of operations 2003 should see the final elements of our paediatric indication of McCune-Albright The tables on this and the previous page portfolio transformation fall into place.
Although exclusivity will last until show our sales and operating profit before believe we are well positioned to absorb the February 2003, sales of Nolvadex and exceptional items.
full year effects of generic competition for tamoxifen have started to decline, partly Prilosec, Nolvadex and Zestril.
Following the through the success of Arimidex, and are Year to 31 December 2002 planned launches of Crestor and Exanta all expected to fall sharply after February 2003.
Growth rates described in this section the elements will be in place to drive sales exclude the effects of exchange rate and earnings growth in 2004 and beyond.
In Europe, Nexium and Symbicort launches movements unless noted otherwise.
This continued and both products are now is consistent with our internal management Gastrointestinal marketed in most countries.
Patents covering reporting and we believe it provides a better Gastrointestinal sales grew by 7% to $6,664 Losec and Zestril expired in the UK and the understanding of underlying trends than million.
In Japan, the using actual growth.
launch of Iressa generated significant sales in The strong growth of Nexium more than offset the second half of 2002.
European markets Our sales increased by 9% from $16,222 declines in Losec Prilosec.
Nexium sales generate 32% of our total sales and Japan million in 2001 to $17,841 million in 2002. were $1,978 million for the year, including 5%.
Operating profit before exceptional items rose $453 million from markets outside the US.
The weaker US dollar increased our There were a further 38 launches in 2002, Investment has continued in R&D and in reported sales growth by 1% whilst there was bringing the total to 76 countries.
The global selling and marketing activities.
In both areas, no significant currency effect on operating PPI market continues to grow strongly prioritisation of resources across the portfolio profit growth.
Earnings per share before around 20% per annum.
Nexium share of is actively managed to avoid committing exceptional items grew by 7% from $1.73 to the PPI market across major markets was resources before opportunities are clear.
Earnings per share after exceptional 16% in October 2002.
In the US, Nexium spend was particularly focused on items decreased from $1.65 to $1.64.
share of total prescriptions for PPI products completing the development programmes for reached 20.5% in December.
Selling and Our sales growth for the year was impacted marketing resources were prioritised to significantly by the decline in our Losec Prilosec sales were down by 18% for recently launched and growth products such Losec Prilosec sales, which fell by 18%.
The 21% decline in the US was as Nexium, Symbicort and Seroquel.
effect is excluded, the sales growth is 23%, broadly in line with the prescription trend.
strong evidence of the positive underlying Sales performance outside the US down As discussed in further detail in the results of momentum of our business.
This growth was 12% was aided by strong growth in Japan operations of the year to 31 December 2002, fuelled by a trebling of Nexium sales, strong up 40% from $69 million to $92 million and we have taken a $350 million exceptional performances from the CNS up 53%, Australia up 25% from $72 million to $95 charge in respect of the US Department of Respiratory up 16% and the Oncology up million.
A generic omeprazole product Justice investigation into the sales and 12% product ranges.
Generic competition became available in the US market on 8 marketing of Zoladex in the US.
for Zestril resulted in a sales growth for December.
In the week ending 17 January Cardiovascular products of just 1%.
2003, Prilosec brand share of total As part of AstraZenecas objective to align omeprazole prescriptions was 47%, a rate with accounting best practice cash discounts The successful launches of Faslodex in the that is consistent with reports of constrained arising from prompt payment of invoices have US, Iressa in Japan, and Symbicort outside supply of generic product.
been reclassified from cost of sales to sales.
the US, combined with Nexium sales, Comparatives have also been reclassified for generated nearly $2.4 billion in sales in 2002 consistency of presentation.
Both sales and up from $651 million in 2001.
Five other AstraZeneca operating profit before exceptional items 2002 2001 2000 $m $m $m Continuing operations 4,356 4,156 3,984 Agrochemicals discontinued 346 4,356 4,156 4,330 AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
com 32 Financial Review continued Cardiovascular Key products sales by therapeutic area 2002 and 2001 Cardiovascular sales grew by 1% to $3,569 million.
% of AstraZeneca total sales 2002 2001 %CER continuing operations $m $m growth Zestril sales have fallen by 18% from 37 Gastrointestinal 6,664 6,190 7 $1,067 million to $877 million as a result of Losec Prilosec 26 4,623 5,578 18 the introduction of generic competition in Nexium 11 1,978 568 the US, where revenues dropped by 24% to $467 million.
20 Cardiovascular 3,569 3,483 1 Zestril 5 877 1,067 18 Sales of Atacand products grew by 36% on a Seloken Toprol-XL 5 901 711 27 global basis in 2002 to $569 million with sales 2 Plendil 3 489 463 5 in the US increasing by 37% to $206 million.
569 410 36 Atacand 3 Tenormin 2 370 404 7 037 Prescriptions continue to grow strongly for Seloken Toprol-XL in the US generating sales 10 Respiratory 1,818 1,539 16 of $617 million up 43%.
Worldwide sales Pulmicort 4 812 766 5 grew by 27% from $711 million to $901 Rhinocort 2 299 265 13 million.
Symbicort 2 299 83 Accolate 1 144 143 2 Plendil sales rose by 5% to $489 million as Oxis 1 120 127 9 037 in 2001, growth in the US up 6% to $209 million was offset by lower growth in the rest 13 Oncology 2,369 2,111 12 of the world.
Zoladex 4 794 718 12 Casodex 4 644 561 15 Respiratory and Inflammation Nolvadex 3 480 618 21 Respiratory sales increased by 16% to Arimidex 2 331 188 75 0 37 $1,818 million.
9 Central Nervous System 1,505 980 53 Symbicort sales for the year were $299 Seroquel 7 1,145 685 67 million, up around 250%.
The product has Zomig 2 328 273 19 037 now been launched in more than 40 countries.
Value share of the fixed Pain Control, Infection combination asthma products across Europe 8 and Other Pharma 1,418 1,496 5 was over 22% in November 2002, with Diprivan 2 443 456 3 notably higher shares achieved in Sweden Merrem 2 285 227 26 48% and Germany 30%.
The regulatory Local anaesthetics 2 432 434 submission for COPD treatment is being Other Pharma Products 1 258 379 31 037 reviewed in the European Union.
3 Others 498 423 16 037 Pulmicort Turbuhaler sales globally reflect the as recently launched, growth rates not meaningful declining inhaled bronchial steroid market in the face of growing acceptance of combination products.
This was more than offset by the strong growth of Pulmicort Arimidex has enhanced its position as the December 2002, the Oncology Drugs Respules in the US up 75%, enabling leading product in the aromatase inhibitor Advisory Committee to the US FDA did not Pulmicort to achieve a 5% global sales market for breast cancer treatment.
Market recommend approval of this indication in the increase for the full year to $812 million.
share has grown as the positive results of US.
Even without the benefit of this new the ATAC trial in early breast cancer have indication, prescriptions for Casodex grew by Rhinocort sales in the US increased by 19% been incorporated into product labels and some 5% in the US market last year.
The for the year to $211 million, fuelled chiefly are being adopted in clinical practice.
Monthly reported sales decline in the US of 23% to by share gains for Rhinocort Aqua in the prescriptions in the US have doubled since $180 million is therefore not indicative of aqueous intranasal steroid market of more December 2001, driving the 127% increase underlying demand, but rather an adverse than three percentage points Rhinocort Aqua in US sales for the year to $134 million.
Sales comparison against wholesaler stockbuilding revenues grew by 39%.
Sales were flat in the outside the US increased by 51% to give total which occurred at the end of 2001. rest of the world resulting in a global 13% global sales growth of 75% to $331 million.
increase in Rhinocort franchise sales to $299 US revenues for Nolvadex in the year were million in 2002.
Sales of Casodex outside of the US increased $337 million, down 27%, as sales of our by 42% to $464 million in 2002 as the use of tamoxifen products fell as a result of the Oncology Casodex 150 mg tablets in the treatment of expiry of our distribution agreement with Barr Oncology sales grew by 12% to $2,369 early prostate cancer has now been Laboratories.
Furthermore, a sharp decline in million.
However, in sales in the US is expected AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
com 33 following the end of exclusivity in February Sales of Merrem grew by 26% for the full year product mix and lower Merck payments 2003. to $285 million, chiefly on the 31% increase reduced cost of sales by 0.6 percentage on sales outside the US.
In the US sales grew points to 25.3 percentage points of sales Sales of Faslodex in the treatment of by 9% to $59 million.
whilst SG&A growth was broadly in-line with advanced breast cancer reached $35 million sales growth.
R&D increased by 0.6% to after eight months in the US market.
A The small sales increase for Diprivan in the 17.2% of sales, principally due to the growth European submission for second line US up 3% to $216 million was the result of in clinical trial costs.
In aggregate, R&D and treatment of advanced breast cancer is growth in the underlying demand for propofol SG&A grew by around 10% at constant planned for the first quarter of 2003. offsetting small market share losses to exchange rates.
Other operating income fell generic products.
This rise did not from $368 million to $243 million reflecting Sales of Iressa for the treatment of inoperable compensate for declines elsewhere and both lower royalty income and product or recurrent non-small cell lung cancer global sales fell by 3% to $443 million.
reached $65 million out of global sales of $67 million in just over four months on the market Other pharmaceutical products fell by 31% As previously disclosed, the US Department in Japan, indicating a high level of acceptance from $379 million to $258 million, mainly as a of Justice has been conducting a civil and in this area of great unmet medical need result of the disposal of the Sular product criminal investigation into the sale and notwithstanding strict precautions introduced range at the beginning of the year.
marketing of Zoladex goserelin acetate locally.
In the US, the FDA has indicated that it implant.
This investigation was prompted by will require an additional three months to May Others the filing of a qui tam complaint by a private 2003 to complete its review of the pending Salick Health Care and Astra Tech achieved party in 1997 and involves allegations of NDA.
A regulatory submission in Europe is sales growth of 20% and 14% in the year to improper submissions of claims to the planned for the first quarter of 2003.
The Marlow Foods sales increased by 8% to Company and federal and state authorities Central Nervous System $114 million: the business saw its first sales are in the process of negotiating a potential CNS sales increased by 53% to $1,505 in the US generating $3 million.
settlement of the civil and criminal claims at million.
As a result, although Geographic analysis no final agreement has been concluded, we Seroquel sales reached the $1 billion In the US sales increased by 10% for the full believe it appropriate to accrue $350 million annualised sales megabrand milestone in year.
Excluding Prilosec, sales growth was to cover estimated settlement costs as an 2002.
Sales grew strongly in the US up 67% 33%, with excellent performances in Nexium, exceptional item.
and in the rest of the world also up 67% Seroquel, Toprol-XL, Pulmicort Respules and to $1,145 million.
Market share of new Arimidex.
Interest and dividend income was $31 million prescriptions in the US market was 19.2% 2001 $113 million for the full year and in December, up 3.7 percentage points in Strong sales performance in France up 13% includes the effects of some small exchange the year annual sales totalled $927 million.
to $1,140 million and Italy up 16% to $765 and revaluation losses.
Seroquel value share of the market in Japan million more than offset declining sales in is now 25% in just over one year on the Germany and the UK, resulting in a 5% Excluding exceptional items, the effective market.
An sNDA submission in the US for increase in Europe for the full year.
Sales tax rate for the full year 2002 was 26.8% use of Seroquel in the treatment of acute growth was driven by Nexium, Symbicort, compared with 28.4% for 2001.
The 2001 mania associated with bipolar disorder Casodex and Seroquel.
tax rate has been restated under FRS19.
manic depressive illness was announced No tax relief has been provided on the on 2 January 2003.
A filing in Europe is A strongly performing product range in exceptional item charge in 2002. planned for the first quarter of 2003.
Oncology including the excellent uptake for Iressa and continued strong growth in Losec We paid a first interim dividend for 2002 Zomig sales for the full year grew by 19% up 40% fuelled the 21% sales growth in on 7 October 2002 of $0.23 per Ordinary to $328 million, with the bulk of the increase Japan for the full year.
A second interim dividend for 2002 arising in Japan up 67% to $14 million, million in 2002, up from $851 million in 2001. of $0.47 per Ordinary Share has been France up 29% to $60 million as well as declared, which the Annual General Meeting from the US up 20% to $177 million.
Research and development will be asked to confirm as the final dividend.
Rapimelt tablets and nasal spray formulations Our R&D costs rose in 2002 from $2,687 This, together with the first interim dividend, have been valuable additions to the product million before exceptional items to $3,069 makes a total of $0.70 for the year in line range in countries where they have been million.
Part of this 14% increase can be with the Groups dividend policy.
Zomig sales in the fourth quarter attributed to exchange fluctuations 4%.
in the absence of unforeseen circumstances in the US appear to reflect some wholesaler anticipates that dividends will be maintained stockbuilding.
Zomig prescriptions in the US Operating margin and retained profit at $0.70 until earnings cover dividends by increased by 11% for the year, in line with the Operating profit before exceptional items between two and three times: thereafter, triptan market overall.
Operating dividends are intended to be grown in line margin of 24.4% was 1.2 percentage points with earnings.
Pain Control, Infection and below prior year.
Currency impacts reduced Other Pharma margin by 0.3% whilst the other 0.9% In 2002, we re-purchased 28.4 million Pain Control, Infection and Other Pharma reduction was largely due to lower other Ordinary Shares nominal value $0.25 each sales fell by 5% to $1,418 million.
Elsewhere, improved for cancellation at a total cost of $1,190 million.
com 34 Financial Review continued Financial position $3,844 million from $2,867 million.
The net Capitalisation The net book value of our assets increased funds are summarised in the note below.
The share re-purchase programme has been from $9,629 million at 31 December 2001 to extended and will continue as an integral part $11,226 million at 31 December 2002.
The Within loans, the 6.3% guarantee notes of the Companys financial management until increase was driven by the net profit for the amounting to $284 million are due for the end of 2003 at a total cost of $4 billion.
We year of $2,836 million and consolidation repayment in 2003. re-purchased 28.4 million shares in 2002 for translation gains of $1,110 million, offset $1,190 million, bringing the total number of by re-purchases of shares and the 2002 Liquidity and capital resources shares re-purchased since the start of the dividends, amounting to $1,190 million and All data in this section is on an actual basis re-purchase programme in 1999 to 65.6 $1,206 million, respectively.
million at a cumulative cost of $2,805 million.
The number of shares in issue at year end Tangible fixed assets Cash flow was 1,719 million.
Our reserves were Our tangible fixed assets amounted to $6,597 Before exceptional cash expenditure, we increased by $1,110 million due to the effect million at the year end 2001 $5,409 million.
generated $5,686 million cash inflow from of exchange rate movements on translation of This includes $1,298 million of construction in operations in 2002, significantly higher than non-dollar denominated assets and liabilities.
progress 2001 $1,119 million, the major the corresponding figure of $4,130 million in Shareholders funds increased by a net elements of which are new manufacturing 2001.
Higher profits before depreciation and $1,586 million to $11,172 million at year end.
capability in Puerto Rico and Sweden, amortisation contributed $300 million, and research facilities in the UK and administrative there were significant working capital inflows, Investments, divestments and capital and other facilities in the US.
particularly from stocks and creditors.
A expenditure significant part of the creditors movements There were no significant acquisitions or Goodwill and intangible fixed assets arises from the timing of payments to Merck.
As discussed in critical accounting policies, Expenditure on exceptional items was a substantial element $1,237 million of our $275 million lower than in 2001 as the Our cash expenditure in 2002 on fixed assets goodwill and intangible assets balance of integration and synergy programmes reach including intangible assets, goodwill and $2,807 million arose as a result of the set up in their conclusion.
Tax cash outflows at $795 fixed asset investments totalled $1,543 1994 and subsequent restructuring in 1998 million were marginally higher than 2001 million net of disposals of $65 million.
This of the Astra Merck joint venture.
A further whilst cash inflows from interest fell to $35 expenditure was broadly similar to the last $742 million relates to the Advanced Payment million as a result of lower returns.
We applied two years and includes the elements in relation to the Merck arrangements the remaining cash in continuing our share discussed above together with a further discussed below.
We also own the marketing re-purchase programme up $110 million instalment to purchase marketing rights of rights to Losec and Plendil in Italy and Spain, from 2001 to $1,190 million, continued $146 million.
The capital expenditures are acquired from Schering Plough in 1999, investment in fixed assets broadly similar financed from internally generated funds.
to 2001 at $1,608 million and dividends $1,234 million.
As a result, our net cash Financial policies Stocks inflow before non-equity financing was Insurance Our stock value has risen from last year to $902 million compared to an outflow in 2001 Our risk management processes are described $2,593 million 2001 $2,402 million.
in the Directors Report on page 46.
An this increase can be attributed to an increase outcome of these processes is that they in levels of stock of products in pre-launch Undrawn committed and uncommitted bank enable us to identify risks which can be partly and early marketing phases as well as facilities at 31 December 2002 totalled $0.5 or entirely mitigated through use of insurance currency fluctuations.
billion with maturities ranging from one to two or which we can self-insure.
Our working capital is sufficient for our best possible premium rates with insurance Debtors and creditors present requirements and includes sufficient providers on the basis of our extensive risk The increase in debtors and creditors reflects cash for our capital programme, share management procedures.
In the current year end timings of settlement of trade re-purchases, and any costs of launching insurance market, level of cover is decreasing creditors and increased trading activity in the new products.
whilst premium rates are increasing.
Rather year together with exchange effects.
than simply paying higher premiums for lower Future operating cash flows may be affected cover we focus our insurance resources on Net funds by a number of factors as outlined in the the most critical areas, or where there is a We have significant net funds which have business background section on page 30. legal requirement, and where we can get best grown due to a cash inflow for the year to AstraZeneca net funds 2002 2001 $m $m Short term investments 3,962 3,118 Cash, net of overdrafts and short term borrowings 524 491 Loans 642 742 Total 3,844 2,867 AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
Risks which we give The transaction exposures that arise from Funding risk particular attention to include product liability, non-local currency intercompany sales and We have significant net funds to finance business interruption, directors and officers transactions with third parties of our ongoing working capital requirements for our liability, and property damage.
subsidiaries are fully hedged using forward operations.
In addition, we also have foreign exchange contracts and purchased guaranteed credit facilities in the amount of Treasury currency options.
$75 million and retain a commercial paper Our financial policies covering the programme should the need arise for management of cash, borrowings and foreign Longer term forecast cash flow currency significant additional funding.
exchange are deliberately conservative and exposure is managed by forecasting cash intended to support our objective of building flows by major currency for the next 12 Sensitivity analysis shareholder value by managing and controlling months on a monthly rolling basis.
The policy The sensitivity analysis, set out in this our financial risks.
Our treasury operations are is to limit the potential downside by hedging Financial Review on page 36, summarises the conducted in accordance with policies and 50%, subject to variation within authorised sensitivity of the market value of our financial procedures approved by the Board.
limits, using a mixture of purchased currency instruments to hypothetical changes in options and forward exchange contracts.
Changes to the The Treasury activities are managed centrally value of the financial instruments are normally from London and over 90% of our cash and In 2002, the US dollar depreciated against all offset by our underlying assets and liabilities.
short term investments are managed directly major currencies.
It is estimated that the effect The range of variables chosen for the from London.
With only limited and of currency movements was to increase our sensitivity analysis reflects our view of specifically approved exceptions, all currency continuing business sales by approximately changes which are reasonably possible over and interest rate hedging is conducted from $111 million and reduce our operating profit a one year period.
Market values are the London.
Operating units benefit from local by $25 million net of hedging benefits.
present value of future cash flows based on currency billing which has the effect of market rates and prices at the valuation date.
consolidating their foreign exchange Interest rate risk exposures back into central Treasury.
The management of our liquid assets and Market values for interest rate risk are loans are co-ordinated and controlled calculated using third party systems which Foreign exchange centrally by our treasury operations.
We have model the present value of the instruments The US dollar is the most significant currency significant positive cash flows and the liquidity based on the market conditions at the for us.
As a consequence we have chosen to of major subsidiaries is co-ordinated in cash valuation date.
For long term debt, a report our results in US dollars and manage pools and concentrated daily in London.
favourable change in market value results in a our exposures against US dollars accordingly.
Interest rate risk is managed according to a decline in the absolute value of debt.
For other Approximately half of our sales in 2002 were benchmark reflecting 90 days duration of net financial instruments a favourable change in denominated in currencies other than the US liquid funds.
Our liquid funds are primarily market value results in an increase in the dollar, while a significant proportion of our invested in US dollars.
manufacturing and R&D costs are denominated in sterling and Swedish kronor.
Our debt has an average maturity of 10 years The sensitivity analysis on page 36 assumes As a result, our operating profit in US dollars and the majority is denominated in US dollars.
an instantaneous 100 basis point change in can be affected by movements in exchange A large portion has been swapped from fixed interest rates in all currencies from their levels rates.
rate into floating rate debt, thereby reducing at 31 December 2002, with all other variables our exposure to downside interest rate held constant.
Currency exposure is managed centrally movements.
using 12 month currency cash flow forecasts Based on the composition of our long term for Swedish kronor, sterling, euro, Japanese Credit exposure debt portfolio as at 31 December 2002 yen, Australian dollar and Canadian dollar and Our exposure to financial counterparty credit which is predominantly floating rate, a 1% monthly updated working capital forecasts for risk is controlled by our treasury team increase in interest rates would result in an the major currencies reported by subsidiaries.
centrally by establishing and monitoring additional $4.5 million in interest being We use derivative financial instruments, counterparty limits.
Our funds are invested incurred per year.
principally currency options and forward almost entirely with counterparties whose foreign exchange contracts, to hedge our credit rating is A or better.
The exchange rate sensitivity analysis on currency exposure.
It is our policy not to page 36 assumes an instantaneous 10% engage in any speculative transactions nor to Trade debtor exposures are managed locally change in foreign currency exchange rates actively hedge through the financial markets in the operating units where they arise.
We are from their levels at 31 December 2002, with currency translation exposures arising from the exposed to customers ranging from large all other variables held constant.
The 10% consolidation of our non-US dollar subsidiaries.
private wholesalers to Government-backed case assumes a 10% strengthening of the agencies and the underlying local economic US dollar against all other currencies and Key controls, applied to transactions in and sovereign risks vary throughout the world.
the 10% case assumes a 10% weakening derivative financial instruments, are to use only Where appropriate we endeavour to minimise of the US dollar.
instruments where good market liquidity exists, risks by the use of trade finance instruments to re-value all financial instruments daily using such as letters of credit and insurance.
current market rates and to sell options only to offset previously purchased options.
com 36 Financial Review continued Ratios As at end and for the year ended 31 December 2002 2001 2000 restated restated Return on shareholders equity % 27.3 30.6 23.2 Equity assets ratio % 51.8 51.8 49.8 Net funds equity ratio % 34.4 29.9 38.4 Number of employees 58,700 54,600 52,300 Sensitivity analysis 31 December 2002 Market value change favourable unfavourable Market value Interest rate Exchange rate 31 December 2002 movement movement 1 % 1 % 10 % 10 % $m $m $m $m $m Cash and short term investments 4,793 7 7 29 29 Long term debt 733 26 32 3 3 Interest and currency swaps 82 Foreign exchange forwards 9 3 3 Foreign exchange options 97 10 150 19 25 39 179 Sensitivity analysis 31 December 2001 Market value change favourable unfavourable Market value Interest rate Exchange rate 31 December 2001 movement movement 1 % 1 % 10 % 10 % $m $m $m $m $m Cash and short term investments 3,897 4 4 13 13 Long term debt 805 20 24 10 10 Interest and currency swaps 70 Foreign exchange forwards 10 10 11 Foreign exchange options 81 9 108 16 20 4 122 AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
com 37 Critical accounting policies and estimates judgement may be required.
With Royalty income Our financial statements are prepared in Prilosec facing generic competition at the accordance with accounting principles end of 2002, we have given particular Royalty income is recorded under Other generally accepted in the United Kingdom attention to the possible level of returns.
Operating Income in the financial UK GAAP and the accounting policies Overall, we believe that our estimates are statements.
Royalties tend to be linked to employed are set out under the heading reasonable.
levels of sales or production by a third Financial Statements Accounting Policies party.
At the time of preparing the financial on pages 63 and 64 of the Companys Annual Similarly, at the time of invoicing sales, statements, we may have to estimate the Report and Form 20-F.
In applying these rebates which could be paid out over the third partys sales or production when policies, we make estimates and following six to nine months are arriving at the royalty income to be assumptions that affect the reported amounts estimated.
These rebates typically arise included in the accounts.
These of assets and liabilities and disclosure of from sales contracts with managed care estimates, which may differ from actual contingent assets and liabilities: the actual organisations and hospitals and from sales, do not result in a material impact on Medicaid best price contracts.
The reported other operating income.
outcome could differ from those estimates.
estimates are made on a customer by customer basis taking into account Sales of intangible assets intellectual Some of these policies require a high level specific contract provisions and are property, brands, goodwill etc of judgement, either because the areas are especially subjective or due to their reviewed each month.
We believe that the most critical believes that it has been reasonable in its A consequence of charging all research accounting policies and significant areas of estimate for future rebates using similar and development expenditure to the judgement and estimation are in revenue methodology to that of 2001.
Inevitably, profit and loss account in the year that it is recognition, research and development, however, such estimates involve incurred which is normal practice in the goodwill and intangible assets, postjudgements on future sales levels and the pharmaceutical industry is that we own retirement benefits, share option extent to which customers will access valuable assets intellectual property, compensation and provisions for contingent different incentive levels.
Experience has brands etc which are not recorded on the liabilities.
shown these estimates to be substantially balance sheet.
We also own acquired accurate.
intangible assets which may be included Revenue recognition.
Revenue represents on the balance sheet see Research and sales of products net of estimated rebates A further feature of the US market is that development below.
As a consequence to external third parties and excludes sales can also be significantly influenced of its regular reviews of product strategy, intercompany income and value added taxes.
from time to time the Company sells such We also receive income from royalties, and Wholesalers often place orders which are assets and generates income.
In a simple from sales of intellectual property, brands and significantly larger than their normal levels situation, the recognition of income may product lines which are included in other of demand ahead of anticipated price be easily defined but often the transfer of operating income.
increases or they may seek to build up or title can require ongoing commitment by run down their inventory levels for other us for example, ongoing manufacturing Sales of products to third parties reasons.
If such speculative orders are arrangements, technology transfer, shipped shortly before a quarter or year transfer of product licences, etc.
In these Sales revenue is recorded as turnover in end it can result in revenue being circumstances, the recognition of our financial statements and valued at the recorded in the current financial period in revenue may be spread over the period of invoiced amount excluding sales and respect of the following years underlying our ongoing commitment.
Profits or value added taxes less estimated demand and distortion of the financial losses from the sale of product related provisions for product returns and results from one period to the next.
intangible assets are classified in Other rebates given to managed care and other Management tracks wholesaler inventory Operating Income and are stated after customers a particular feature in the US.
levels by product using its own and third taking account of product disposal costs, Cash discounts for prompt payment are party estimates and, where we believe the valuation of which includes a degree also deducted from sales.
Revenue is such distortions occur, we disclose in the of judgement.
recognised when title passes to the financial review for each product where customer which is usually either on shipments may be out of line with Research and development.
Our business is shipment or on receipt of goods by the underlying prescription trends.
The underpinned by our marketed products and wholesaler depending on local trading Company does not offer any incentives to development portfolio: the research and terms.
Industry practice in the US allows encourage wholesaler speculative buying development expenditure to generate these wholesalers and pharmacies to return and attempts where possible to restrict products is charged to the profit and loss unused inventories within six months of shipments to underlying demand when account in the year that it is incurred.
At point of sale, such speculation occurs.
policy is in line with practice adopted by all management estimate the quantity and major pharmaceutical companies.
value of goods which may ultimately be We offer cash discounts on prompt returned.
Our returns provisions are settlement of invoices and, once again, Purchase of intellectual property, product based on actual experience over the this is a particular feature in the US, rights, etc to supplement the Groups R&D preceding 12 months, although in certain although it is seen elsewhere.
As noted portfolio can lead to differing accounting situations, for example, a new product above, we deduct cash discounts from treatment depending on managements launch or at patent expiry, further revenue.
assessment of the nature of the acquisition AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
com 38 Financial Review continued and the degree of risk involved.
For example, these as contingent liabilities.
These are not valuation basis, which is appropriate for payments in respect of rights to a compound provided for but are disclosed in the notes.
traded options but less so for more restrictive in early stage development would normally be Further details of these are set out in Note 34 employee grants, we estimate an additional expensed immediately against income on the on page 101.
Although there can be no charge of approximately $122 million would basis that, at this point, the probability of the assurance regarding the outcome of these arise.
This would result in a charge to profit compound successfully reaching the market proceedings, we do not expect them to have and loss but would have no impact on our net place is still low.
Payments in respect of rights a materially adverse effect on our financial assets or on our current or future cash flows.
to a compound in late stages of development, position or profitability.
however, or to one already being marketed, Off-balance sheet transactions, would probably be capitalised as an We also have significant commitments which contingent liabilities and commitments intangible asset see Goodwill and intangible are not currently recognised in the balance assets below as the prospect of success is sheet arising from our relationship with Merck.
Details of our contingent liabilities and much greater.
There have been no material These are described more fully in Offcommitments are set out in Note 34 to the capitalisation of or charges for such items balance sheet transactions, contingent Financial Statements.
We have no offduring 2002. liabilities and commitments.
balance sheet entities and our hedging activities are non speculative.
We account for the significant investments in goodwill and pension costs relating to the UK retirement Arrangements with Merck intangible assets as a result of acquisitions of plans under SSAP 24 and under local businesses and purchases of such assets as accounting practices for non UK-subsidiaries Introduction product development and marketing rights.
due to the cost and difficulty of obtaining In 1998, Astra and Merck & Co Inc Under UK GAAP these are amortised over SSAP 24 information for non-UK schemes.
In restructured their joint venture the their estimated useful lives.
Changes in these all cases, the pension costs are assessed in restructuring which had been established lives would result in different effects on the accordance with the advice of independent some years earlier for the purpose of selling profit and loss account.
We estimate that a qualified actuaries but require the exercise of and marketing certain Astra products in the one year reduction in the estimated useful significant judgement in relation to United States.
Under the restructuring a US lives of goodwill and intangible assets would assumptions for future salary and pension limited partnership, in which Merck is the increase the annual amortisation charge by increases, long term price inflation and limited partner and we are the general partner, $23 million.
A substantial part of our investment returns.
SSAP 24 permits flexibility was set up.
The restructuring agreement investments in intangible assets and goodwill in the actual assumptions and bases to be provided for certain termination clauses, and relate to the restructuring of the Astra-Merck used and the application of different provisions for amending these clauses on the joint venture in 1998 and we are satisfied that assumptions could have a significant effect occurrence of certain defined events, the carrying value is fully justified by future on the amounts reflected in the financial including a merger by Astra.
Goodwill and intangible assets are statements.
Management considers that the reviewed for impairment where there are assumptions and bases detailed in Note 32 Under the terms of the 1998 restructuring, the indications that their carrying values may not are appropriate for the business.
merger between Astra and Zeneca in 1999 be recoverable and any impairments are triggered two one-time payments from us to charged to the profit and loss account.
Tests The off-balance sheet aspects of postMerck: for impairment are based on discounted retirement benefits are discussed on page 39. cash flow projections, which require a Lump Sum Payment of $809 million, which management to estimate both future cash On pages 94 to 96, we also provide additional was charged to profit and loss account, flows and an appropriate risk-adjusted disclosures in accordance with FRS17.
Had as a result of which Merck relinquished discount rate.
Such estimates are inherently FRS17 been applied the additional charge any rights to Zeneca products: and subjective.
No impairments to goodwill or to profit and loss would have been about intangibles 2001 $nil, 2000 $24 million were $30 million.
an Advance Payment of $967 million.
This Advance Payment was calculated as Share option compensation.
Through the the then net present value of $2.8 billion Under UK GAAP, the merger of Astra and remuneration committee we offer share discounted from 2008 to the date of Zeneca in 1999 was recorded as a merger options to certain employees as part of their payment of a rate of 13% per annum and of equals pooling of interests.
Under US compensation and benefits packages, causes Merck to relinquish any rights to GAAP, the merger has been accounted for designed to improve alignment of the future Astra products with no existing or as the acquisition of Astra by Zeneca as interests of employees with shareholders.
pending US patents at the time of the discussed in more detail on page 42.
Details of these are given in Note 33.
that, at some point, international, UK and US Contingent liabilities.
In the normal course of accounting standards will require share We make ongoing payments to Merck based business, contingent liabilities may arise from option grants to be valued and charged on sales of certain of our products in the US environmental liabilities connected with our against income.
At present US GAAP requires the contingent payments on the current or former sites, from product specific some share option costs to be charged to the agreement products as well as certain and general legal proceedings, or from profit and loss account and stipulates other partnership returns, the latter of which guarantees.
Where we believe that potential disclosure of the cost should all eligible are not material to the Group.
As a result of liabilities have a low probability of crystallising options be expensed as set out on page the 1999 merger, these contingent payments or are very difficult to quantify reliably, we treat 118.
Using the Black-Scholes model as a excluding those in respect of Prilosec and AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
com 39 Nexium are subject to defined annual The precise amount of settlements with plans where benefits are based on minimum amounts between 2002 and 2007 Merck under the Partial Redemption and the employees length of service and final ranging from $125 million to $225 million.
First Option cannot be determined at this pensionable pay.
The UK and US schemes time, as some of the payments are based on were closed to new entrants in 2000.
All new Our payments have exceeded the minimum calculations based on trading performance employees in these countries are offered level in 2002 and we have no reason to between 2005 and 2007, and another is defined contribution schemes.
believe that the annual payments in the future contingent upon Merck exercising the First will fall below the minimum obligations.
However, if Merck does exercise this Under FRS17, the disclosures on page 95 also performs certain manufacturing stages option, the combined effect will involve a highlight a deficit of $637 million, after for certain agreement products.
minimum amount payable to Merck in 2008 deferred tax, for all Group post-retirement of approximately $4.7 billion.
If we exercise defined benefit schemes.
FRS17 prescribes The terms of the 1998 restructuring provide this option in 2010, the combined effect will detailed rules for the calculation of scheme for the following events: involve a minimum aggregate amount assets and liabilities and indicates the net payable to Merck in 2008 and 2010 of accounting surplus or deficit that would exist Partial Redemption approximately $4.7 billion.
if the schemes were wound up at the balance First Option sheet date.
Fluctuations in investment Second Option Finally, in 2008, Merck will repay to us a loan in conditions and or FRS17 prescribed the amount of $1.4 billion made at the time of assumptions can result in significant volatility These are described in more detail below.
in the surplus or deficit.
Partial Redemption Second Option Pension and other post-retirement schemes, In 2008, there will be a partial redemption of A Second Option exists whereby we have the however, are managed over the long term.
Mercks limited partnership interest which option to re-purchase Mercks interests in Investment and liability decisions are based will end Mercks rights to contingent Prilosec and Nexium in the US.
This option is on underlying actuarial and economic payments in respect of certain agreement exercisable by us two years after the exercise circumstance with the intention of ensuring products by distribution to Merck of an of the First Option in either 2008 or 2010. that the schemes have sufficient assets to amount calculated as a multiple of the Exercise of the Second Option by us at a later meet liabilities as they fall due rather than previous three years contingent payments on date is also provided for in 2017 or if meeting accounting requirements.
This the relevant products, plus $750 million.
combined annual sales of the two products actuarial approach tends to produce less fall below a minimum amount provided, in volatility than is likely under FRS17.
First Option each case only so long as the First Option has In 2008 a calculation will be made of the been exercised.
The exercise price for the The UK pension plan is the largest single Appraised Value, being the net present Second Option is the fair value of these scheme in the Group.
At the last actuarial value of the future contingent payments product rights as determined at the time of valuation at 31 March 2002, the market value in respect of all other agreement products exercise.
of the funds assets represented 90.1% of its not covered by the Partial Redemption other liabilities as valued on the actuarys funding than Prilosec and Nexium.
Payment of this If the Second Option is exercised, Merck will basis.
The trustee manages both investments amount to Merck in 2008 is, however, have no further rights to contingent payments and liabilities closely.
In particular, over the last contingent on Mercks exercise of the First from us.
12 months it has increased the weighting of Option.
Exercise of the First Option will require the bond portfolio that now represents 62.4% us to re-purchase Mercks interest in these Accounting treatment of the asset portfolio, compared with 58.2% a products.
Should Merck not exercise this Under current UK and US generally accepted year ago.
As a result, the sterling value of the option in 2008, we may exercise it in 2010 accounting principles, we believe that the asset portfolio decreased by only 2.8% during for a sum equal to the 2008 Appraised Value.
payments described under the three 2002, significantly better than the UK or If neither Merck nor we exercise the option, headings above are likely to constitute global equity markets.
The Company has the contingent payment arrangements in purchase consideration in respect of future indicated its intention to target a solvency respect of these agreement products will trading rights and, accordingly, would be ratio of 91% following the 2003 actuarial continue and the Appraised Value will not capitalised within the goodwill and valuation, and to restore full solvency over a be paid.
intangible assets category and amortised, period of around 15 years.
In addition, in 2008 there will be a true up New accounting standards of the Advance Payment.
The calculation of Post-retirement benefits New UK or US applicable accounting this will be based on a multiple of the previous We offer post-retirement benefit plans which standards which have been issued both three years contingent payments in respect cover many of our employees around the adopted and not yet adopted are discussed of all the agreement products with the world.
In keeping with local terms and on pages 62 and 115 respectively.
We exception of Prilosec and Nexium, plus conditions, most of these plans are defined implemented FRS19 Deferred Tax in full in other defined amounts, which are then contribution in nature where the resulting 2002 and have complied with the disclosure reduced by the Appraised Value whether profit and loss account charge is fixed at a set requirements of FRS17 Retirement paid or not, the Partial Redemption and level or is a set percentage of employees pay.
Benefits: details are set out on page 62 and the Advance Payment.
This could result However, several plans, mainly in the UK Note 32 respectively.
The effects of the in a further payment by us to Merck or a which has by far the largest single scheme, impact of SFAS No 144 Accounting for the payment by Merck to us.
the US and Sweden, are defined benefit Impairment of Disposal of Long-Lived Assets AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
com 40 Financial Review continued was not to be material.
The adoption of SFAS Key products sales by therapeutic area 2001 and 2000 No 141 Business Combinations and SFAS % of AstraZeneca total sales 2001 2000 %CER No 142 Goodwill and Other Intangible continuing operations $m $m growth Assets resulted in an increase in US net 38 Gastrointestinal 6,190 6,214 2 income of about $755 million and no impact Losec Prilosec 34 5,578 6,152 7 on US shareholders funds as a result of Nexium 4 568 17 impairment.
The effects of the impact of SFAS No 143 Accounting for Asset Retirement 21 Cardiovascular 3,483 3,431 6 Obligations, SFAS No 146 Accounting for Zestril 6 1,067 1,163 6 Costs Associated with Exit or Disposal Seloken Toprol-XL 4 711 569 28 Activities and SFAS No 148 Accounting for Plendil 2 3 463 473 2 Stock Based compensation are not expected Atacand 3 410 290 46 to be material.
Tenormin 2 404 469 7 038 International accounting 10 Respiratory 1,539 1,361 17 Under current European proposals, we Pulmicort 4 766 700 13 will be required to adopt International Rhinocort 2 265 218 25 Financial Reporting Standards IFRSs Accolate 1 143 149 2 and International Accounting Standards Bricanyl 1 107 125 8 IASs in the preparation of our financial Oxis 1 127 116 15 statements from 2005 onwards.
The Symbicort 1 83 transitional arrangements for implementation 038 of IFRSs and IASs have not been finalised 13 Oncology 2,111 1,902 16 by the regulatory bodies.
However, in our Zoladex 4 718 723 5 opinion, the net profit and shareholders Nolvadex 4 618 567 12 funds in accordance with current international Casodex 3 561 426 38 standards are not significantly different from Arimidex 1 188 156 26 those presented under UK GAAP.
0 38 6 Central Nervous System 980 669 49 The following information is provided in Seroquel 4 685 412 68 accordance with US requirements.
Zomig 2 273 233 20 038 Year to 31 December 2001 Pain Control, Infection Growth rates described in this section 9 and Other Pharma 1,496 1,610 exclude the effects of exchange rate Diprivan 3 456 502 5 movements unless noted otherwise.
Merrem 1 227 170 40 Comparisons with the previous year are in Local anaesthetics 3 434 383 19 terms of our continuing operations.
Operating 038 as recently launched, growth rates not meaningful profit before exceptional items grew by 6%.
The strength of the US dollar reduced reported sales and profits by 4% and 2%, respectively.
Earnings per share before exceptional items 16.3% share of new prescriptions in the US phasing of wholesaler shipments as well as grew by 11% to $1.73.
Excluding the PPI market after only nine months.
In the rest higher rebates contributed to a worldwide Gastrointestinal area, sales growth for 2001 of the world, sales were $122 million by the reduction in sales of 6% to $1,067 million.
was 12% based on strong results from the end of the year Nexium had been launched in Prescription increases for Seloken Toprol-XL Respiratory up 17%, Oncology up 16% 38 countries.
Losec sales fell by 7% to in the US, aided by the new indication, led to a and CNS up 49% areas.
The US decline of 13% was 47% increase in sales value contributing to sales were up 2% in the year, with Losec sales caused largely by reduced stocks of the the 28% worldwide growth to $711 million.
outside of the US growing by 4%.
In the US, product being held by wholesalers but also by Atacand continued to perform well across all Losec Prilosec sales decreased by 13%, the switch of prescriptions to Nexium.
This major markets with sales in the US and in the offset by strong Nexium performance leaving was offset, in part, by an overall 4% sales rest of the world growing by 29% and 58%, Gastrointestinal sales 2% lower than 2000. increase elsewhere.
respectively, to a total of $410 million.
Plendil worldwide sales increased by 2% to $463 Gastrointestinal Cardiovascular million: growth in the US of 6% was offset by Gastrointestinal sales grew by 2% to $6,190 Cardiovascular sales grew by 6% to $3,483 declines in Europe and the rest of the world of million.
Nexium sales in the US totalled $446 million Although the underlying prescription demand Respiratory and Inflammation and in December 2001 accounted for a for Zestril in the US increased, uneven Respiratory and Inflammation sales grew by AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
Geographic analysis During 2001, the merger related synergy and Sales growth in the US was led by the integration programme initiated in 1999 was successful launch of Nexium, which completed, resulting in an exceptional charge Total Pulmicort sales were $766 million, an increase of 13% driven by US growth of 81%.
generated $446 million in just nine months of $202 million.
An exceptional profit of $10 Rhinocort Aqua increased its share of the US on the market.
Excluding sales of million on sale of fixed assets was recorded in aqueous intranasal steroid segment of the Losec Prilosec, sales growth was 28% for the the year.
rhinitis market contributing towards the full year, with strong performances from growth of Rhinocort worldwide of 25% to Seroquel, Toprol-XL and Faslodex.
Our 50% interest in the seeds company $265 million.
Symbicort was launched in the Advanta BV resulted in sales attributed to us major markets in Europe and 23 countries in Double digit growth in France and Italy of $183 million.
In 2001 we settled the dispute total.
Rapid market penetration was achieved contributed to good performance in Europe.
with our joint venture partner Koninklijke in many of these markets in a matter of weeks This performance was offset by declines in VanderHave Groep BV over certain aspects after launch.
Product highlights in the of the shareholders agreement.
region included the launches of Nexium and Oncology Symbicort, as well as good growth from We recorded net interest and dividend Oncology sales grew by 16% to $2,111 Atacand, Casodex and Seroquel.
income of $113 million compared with $138 million.
Falling rates had an adverse Strong growth in Losec up 85% and effect on the interest income.
Casodex is the worlds leading anti-androgen Casodex up 56% and the launches of for the treatment of prostate cancer.
Strong Seroquel, Arimidex and Zomig led to excellent The taxation charge for continuing operations growth was reported in all major markets with results in Japan.
before exceptional items was $1,214 million sales increasing to $561 million worldwide.
representing an effective rate of 28% 2000 Arimidex remains the leading product in the Research and development 35%.
The total tax charge, including aromatase inhibitor market.
Sales in the US Our R&D expenditure totalled $2,687 million exceptional item effects and discontinued were up 11%, and grew by 33% in the rest of for 2001, an increase of $67 million from operations, was $1,160 million compared to the world, to reach $188 million worldwide.
The level of the cost was reduced due $1,425 million in 2000.
Nolvadex sales increased by 12% to $618 to the effect of lower sterling and kronor million driven by strong growth in the US exchange rates and the synergy and Synergy and integration programme where sales reached $462 million, up 18%.
integration activities which realised cost Following completion of the merger in 1999, benefits of approximately $180 million for the we established integration task forces to Central Nervous System year.
Investment in facilities continued, consolidate the operations of the newly CNS sales rose by 49% to $980 million.
particularly in Boston, US and Bangalore, merged Group, remove duplicate activities India.
throughout the organisation and rationalise In 2001 sales of Seroquel in the US were up the number of facilities around the world.
The 51% to $555 million, in line with a strong Operating margin and retained profit costs of the synergy and integration growth in prescriptions.
With the successful Our operating profit before exceptional items programme were incurred fully by the end of launch in Japan and continued growth in grew by 6% to $4,156 million.
2001 at a total cost of $1,388 million.
Europe, sales outside the US grew to $130 million.
Sales of Zomig increased by 20% to In 2001 currency reduced our operating Cash flow $273 million.
The August 2001 launch in profits by 2%.
The adverse effect of the euro In 2001 we generated cash from operating Japan and good growth in Europe were the was partially offset by a favourable impact activities before exceptional items amounting key contributors.
In the US, the Zomig share from our sterling and kronor cost base.
The to $4,130 million compared to $4,992 million of new prescriptions increased above 15%.
operating margin for the year was 25.6%, in 2000.
The reduction is almost entirely 0.3 percentage points higher than 2000. attributable to the effects of the demerger of Pain Control and Infection Excluding the effect of the reclassification of Zeneca Agrochemicals and one-off Merrem enjoyed good growth in Europe $120 million of distribution costs, cost of sales accelerated creditor settlement.
After the where sales were up 21% and continued as a percentage of sales was broadly similar 2000 final dividend and 2001 first interim market share gains in the US led to strong to 2000. dividend $1,236 million, capital expenditure growth for the year.
Diprivan sales reduced by and financial investment of $1,543 million, 5% in the US, a trend reflected elsewhere Our R&D costs for the year was 16.6% of exceptional item costs of $368 million, tax except for Japan where sales increased by sales, broadly unchanged from 2000. payments of $792 million and share issues 21% to $51 million.
Worldwide sales reduced Increases in R&D expenditure to support the and re-purchases of $994 million, our net by 4% to $456 million.
megabrand launches were offset by currency cash outflow before non-equity financing was benefits, particularly from the Swedish sites.
This compares to an equivalent Others We recorded increased selling costs as a inflow in 2000 of $1,314 million, augmented Salick Health Care sales grew by 10% to result of the new product launches and field by $909 million of net cash repayment from $194 million: Astra Tech sales rose by 19% to force expansion, particularly in the US, whilst Syngenta AG on the demerger of the Zeneca $126 million driven by growth in Europe, the general and administrative costs continued to Agrochemicals business.
major market for the business.
Marlow Foods be tightly controlled.
Other operating income, saw a strong performance, with sales which included gains from product growing by 22% to $103 million.
rationalisation, increased to $368 million for the full year 2.3% of sales.
com 42 Financial Review continued Investments, divestments and capital Following the adoption of SFAS No.
142, we Taxation expenditure are no longer amortising the group goodwill Total taxation amounted to $1,035 million, There were no significant acquisitions or element, but are performing annual an effective rate of 31% compared with disposals in 2001. impairment tests on all our US GAAP goodwill 44.8% in 2001.
The cessation of amortisation balances.
These tests show that our US of goodwill, which did not attract tax relief, In 2001, cash expenditure on fixed assets GAAP goodwill balances are not impaired.
was the major factor in the rate improvement.
Major projects included a new business centre in the US, Sales from continuing operations rose from Taxation on continuing operations in 2001 manufacturing facilities for new products in $16,222 million in 2001 to $17,841 million in amounted to a charge of $1,109 million the UK, Puerto Rico and Sweden, together 2002.
The principal drivers of this growth compared to a charge of $969 million in with ongoing research and development were improved performances from Nexium, 2000. facility costs.
This compared with a net cash Symbicort and Seroquel, offset by falls in outflow in 2000 of $1,426 million, again Zestril and Losec.
Discontinued operations focused on manufacturing facilities, including The 2000 net income from discontinued resource in France and research premises in Net income under US GAAP has increased operations includes the results of Zeneca the UK and the US.
Our capital expenditures from $1,397 million to $2,279 million.
These Agrochemicals up until its demerger on 13 are financed from internally generated funds.
increases are as a result of both higher sales November 2000. and the cessation of amortisation of goodwill.
US GAAP We estimate that the latter has improved Cash flow Our Financial Statements have been profit by $755 million.
In 2002 operating activities produced cash prepared in accordance with UK GAAP which inflows of $4,833 million after tax outflows of differs in certain significant respects from US Further details of the impact of the differences $795 million and interest inflows of $46 GAAP.
In particular, under US GAAP, the between UK GAAP and US GAAP are set out million.
There was a cash outflow in respect of AstraZeneca merger has been accounted for in the Additional Information for US Investors investing activities of $2,349 million, reflecting as a purchase accounting acquisition of Astra on pages 113 to 122. further investment in short term investments AB Astra by Zeneca Group PLC Zeneca.
Financing cash outflows Although there are several differences 2001 compared with 2000 absorbed $2,506 million through the share between our net income and assets under Sales from continuing operations US GAAP re-purchase programme $1,190 million and UK and US GAAP, the difference in grew by $639 million from $15,583 million in equity dividends $1,234 million.
accounting for the merger with Astra 2000 to $16,222 million in 2001.
Organic represents substantially all of the growth from existing products, together with In 2001 operating activities generated net adjustments.
a significant contribution from Nexium were cash of $3,126 million after exceptional cash the principal reasons for this growth.
There was a cash Results of continuing operations outflow in respect of investing activities of US GAAP In Europe sales grew to $5,238 million and in $1,327 million, comprising mainly of capital The table below shows the trend of sales the US to $8,483 million, again driven by expenditure of $1,582 million.
Financing cash under US GAAP for our continuing established products and Nexium.
outflows totalled $2,195 million, the principal operations.
payments being in respect of the share Operating income for the year was $2,286 re-purchase programme $1,080 million and 2002 compared with 2001 million compared with $1,693 million in 2000. equity dividends $1,236 million.
The US GAAP treatment of the merger under Both years were impacted by amortisation purchase accounting gave rise to additional charges arising from the acquisition of Astra Net cash of $3,554 million was generated by goodwill and intangible assets with net book total goodwill amortisation amounting to operating activities in 2000, after exceptional values at 31 December 2002 of $12,692 $728 million in 2001 ceased with effect from cash outflows of $809 million.
There was a million and of $7,479 million, respectively.
cash outflow in respect of investing activities Sales of continuing operations in each geographic area in which customers are located US GAAP 2002 2001 2000 reclassified reclassified $m $m $m UK 623 759 787 Continental Europe 5,072 4,479 4,359 The Americas 10,287 9,353 8,799 Asia, Africa and Australasia 1,859 1,631 1,638 Total 17,841 16,222 15,583 AstraZeneca Annual Report and Form 20-F 2002 Financial Review www.
com 43 of $1,294 million representing, primarily, capital expenditure of $1,460 million offset by the repayment of debt by Syngenta AG of $909 million, in connection with the demerger of Zeneca Agrochemicals.
Financing cash outflows totalled $1,620 million, the principal elements being the share re-purchase programme of $353 million and dividend payments of $1,220 million.
Net assets Net assets at 31 December 2002, in accordance with US GAAP, are significantly higher than those under UK GAAP as a result of the acquisition accounting for Astra.
The goodwill arising on the acquisition of Astra had a net book value of $12.9 billion $11.1 billion at 31 December 2001 and fixed assets were $7.8 billion $8.1 billion at 31 December 2001.
These effects were partly offset by approximately $2.3 billion $2.3 billion in 2001 of other adjustments being principally deferred tax liabilities related to the acquisition.
Accordingly, of our net asset value under US GAAP at 31 December 2002 of $30.2 billion, $16.2 billion is attributable to fixed assets, $13.6 billion to goodwill and $2.8 billion to deferred tax.
